Answers are grounded in this paper and cite their sources.
To the Editor.— Photoinactivation therapy for herpes simplex has become a controversial issue since the publication of an observation that herpesvirus photoinactivated by neutral red dye still retained its oncogenicity.1TheMedical Letter on Drugs and Therapeuticscautioned practicing physicians that the use of photoinactivation therapy for herpes simplex might be risky because of the possibility of cancer production.2Timemagazine picked up the issue and introduced it to the public. A drug bulletin was issued by the Food and Drug Administration echoing the potential risk of this new form of therapy.3These warnings made it sound as if it was an established fact that photoinactivation therapy could lead to oncogenesis. On the other hand, Melnick and Wallis tried to repeat the experiments of Rapp et al and were unable to confirm the observation that herpesvirus photoinactivated by neutral red dye still retained its oncogenicity.4 Thus,
No takes yet. Share an insight, caveat, or question.
Te‐Wen Chang (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: